Characteristics
|
Ipsilateral Breast Events (IBE)
|
in situ IBEs
|
invasive IBEs
|
Invasive Breast Cancer Recurrence (IBCR)
|
---|
Among BCS (n = 359)
|
BCS
|
BCS
|
Among all (n = 458)
|
---|
|
HR (95 % CI)
|
HR (95 % CI)
|
HR (95 % CI)
|
HR (95 % CI)
|
---|
Age (years)
| | | | |
< 50
|
Reference
|
Reference
|
Reference
|
Reference
|
50–65
|
0.77 (0.44–1.31)
|
0.92 (0.41–2.05)
|
0.63 (0.30–1.32)
|
0.68 (0.41–1.12)
|
> 65
|
1.19 (0.67–2.12)
|
1.31 (0.55–3.11)
|
1.09 (0.50–2.37)
|
0.98 (0.57–1.66)
|
Detection mode
| | | | |
Screening
|
Reference
|
Reference
|
Reference
|
Reference
|
Clinically
|
1.78 (1.04–3.07)
|
1.78 (0.81–3.91)
|
2.09 (0.98–4.42)
|
1.47 (0.93–2.35)
|
Type of Surgery
| | | | |
BCS
|
-
|
-
|
-
|
Reference
|
Mastectomy
|
-
|
-
|
-
|
0.55 (0.29–1.03)
|
RT after BCS
| | | | |
No
|
Reference
|
Reference
|
Reference
|
Reference
|
Yes
|
0.53 (0.33–0.86)
|
0.50 (0.25–1.01)
|
0.51 (0.27–0.98)
|
0.91 (0.59–1.41)
|
Tumor size (mm)
| | | | |
≤ 25
|
Reference
|
Reference
|
Reference
|
Reference
|
> 25 / multifocal
|
1.14 (0.71–1.83)
|
1.88 (0.97–3.62)
|
0.64 (0.30–1.34)
|
0.89 (0.55–1.45)
|
Nuclear grade
| | | | |
Grade 1
|
Reference
|
Reference
|
Reference
|
Reference
|
Grade 2
|
0.90 (0.41–1.96)
|
1.05 (0.30–3.63)
|
0.73 (0.27–1.99)
|
0.82 (0.38–1.77)
|
Grade 3
|
0.83 (0.39–1.79)
|
1.03 (0.30–3.49)
|
0.63 (0.23–1.69)
|
0.64 (0.30–1.37)
|
ER status
| | | | |
Negative
|
Reference
|
Reference
|
Reference
|
Reference
|
Positive
|
0.90 (0.52–1.55)
|
0.80 (0.38–1.71)
|
1.02 (0.47–2.22)
|
1.16 (0.70–1.93)
|
PR status
| | | | |
Negative
|
Reference
|
Reference
|
Reference
|
Reference
|
Positive
|
0.83 (0.52–1.32)
|
1.04 (0.53–2.02)
|
0.66 (0.35–1.27)
|
1.06 (0.69–1.63)
|
- RT radiotherapy, BCS breast conserving surgery, IBE ipsilateral breast events, IBCR invasive breast cancer recurrence